Stay updated on Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.
Latest updates to the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page
- Check5 days agoChange DetectedAdded a consolidated Locations section listing Florida, Maryland, and New York sites. Removed the prior state-specific location subsections; page revision updated to v3.3.3.SummaryDifference0.4%
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the ClinicalTrials.gov page. No substantive changes to the study details are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check41 days agoChange DetectedA general government funding/operating status notice has been removed from the page. This does not affect the study details, eligibility criteria, or other trial information.SummaryDifference0.4%
- Check55 days agoChange DetectedThe page shows updated record metadata (latest update 2025-02-10) with no changes to core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check84 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%
- Check91 days agoChange DetectedPage updates include new contact details and a version bump from v3.0.2 to v3.1.0, indicating an updated revision without broader content changes.SummaryDifference0.1%
Stay in the know with updates to Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Post-HLA Mismatched BMT in Sarcoma Clinical Trial page.